JPRN-UMIN000007022已完成1 期
Phase l and Phase ll Study of S-1+oxaliplatin (SOX)+cetuximab as first Line therapy in metastatic colorectal cancer with EGFR-detectable and KRAS wild type - JACCRO CC-06 study
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 56
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 79years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Synchronous multiple malignancy or metachronous multiple malignancy within 5 years disease free interval 2. Symptomatic brain metastases 3. Severe infectious disease 4. Interstitial lung disease or pulmonary fibrosis 5. Comorbidity or history of heart failure 6. Sensory alteration or paresthesia interfering with function 7. Large quantity of pleural, abdominal or cardiac effusion 8. Severe comorbidity (renal failure, liver failure, hypertension, etc) 9. Prior radiotherapy for primary and metastases tumors 10. Men/women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test 11. History of severe allergy 12. History of allergy for L-OHP and other platinating agent 13. Prior treatment of cetuximab or L-OHP or TS-1 14. Administration of flucytosine 15. Any other cases who are regarded as inadequate for study enrollment by investigators
研究者
相似试验
已完成
1 期
A Phase I/II Study of S-1 and Oxaliplatin Combined With Radiation for Preoperative Locally Advanced Rectal CarcinomaColorectal CancerJPRN-UMIN000017450Japan Clinical Cancer Research Organization45
已完成
2 期
Phase II study of S-1 plus oxaliplatin (130 mg/m2, every 3 weeks) for advanced gastric cancerJPRN-UMIN000016973Shizuoka Cancer Center25
已完成
3 期
Phase III Adjuvant Chemotherapy of S-1 plus Oxaliplatin for Colorecrtal Cancer (ACTS-CC 02)JPRN-jRCT1080221040Taiho Pharmaceutical Co., Ltd.1,200
已完成
2 期
Efficacy and safety of S-1 plus oxaliplatin (C-SOX) as adjuvant chemotherapy for Stage III colon cancer.Colon cancerJPRN-UMIN000012618Kyushu Study group of Clinical Cancer(KSCC)85
未知
3 期
Randomized phase III study of S-1 plus oxaliplatin compared with S-1 plus cisplatin as first-line therapy for advanced or recurrent gastric cancerAdvanced or recurrent gastric cancerJPRN-jRCT2080220988Yakult Honsha Co.,Ltd.